PT1653943E - Derivados de catecol para o tratamento do cancro - Google Patents

Derivados de catecol para o tratamento do cancro Download PDF

Info

Publication number
PT1653943E
PT1653943E PT04777151T PT04777151T PT1653943E PT 1653943 E PT1653943 E PT 1653943E PT 04777151 T PT04777151 T PT 04777151T PT 04777151 T PT04777151 T PT 04777151T PT 1653943 E PT1653943 E PT 1653943E
Authority
PT
Portugal
Prior art keywords
alkyl
medicament
catecol
derivatives
cancer treatment
Prior art date
Application number
PT04777151T
Other languages
English (en)
Portuguese (pt)
Inventor
John C Reed
Maurizio Pellecchia
Original Assignee
Burnham Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burnham Inst filed Critical Burnham Inst
Publication of PT1653943E publication Critical patent/PT1653943E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT04777151T 2003-06-25 2004-06-25 Derivados de catecol para o tratamento do cancro PT1653943E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48288603P 2003-06-25 2003-06-25

Publications (1)

Publication Number Publication Date
PT1653943E true PT1653943E (pt) 2008-05-23

Family

ID=34102647

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04777151T PT1653943E (pt) 2003-06-25 2004-06-25 Derivados de catecol para o tratamento do cancro

Country Status (13)

Country Link
US (3) US7812058B2 (enExample)
EP (2) EP1653943B3 (enExample)
JP (2) JP2007524633A (enExample)
AT (2) ATE387911T1 (enExample)
AU (1) AU2004258867B2 (enExample)
CA (1) CA2529507C (enExample)
DE (2) DE602004012279T3 (enExample)
DK (1) DK1653943T4 (enExample)
ES (2) ES2303096T7 (enExample)
PL (1) PL1653943T6 (enExample)
PT (1) PT1653943E (enExample)
SI (1) SI1653943T1 (enExample)
WO (1) WO2005009434A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432304B2 (en) 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
US7354928B2 (en) * 2001-11-01 2008-04-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at Bcl-2
DE602004012279T3 (de) 2003-06-25 2010-07-15 The Burnham Institute, La Jolla Katecholderivate zur behandlung von krebs
WO2005094804A1 (en) * 2004-03-25 2005-10-13 The Regents Of The University Of Michigan Gossypol co-crystals and the use thereof
US20060144723A1 (en) * 2004-11-02 2006-07-06 Mary Fuller Device for securing valuables
CN101883486B (zh) * 2007-10-01 2014-09-17 阿森达治疗学股份有限公司 制备r-棉酚l-苯丙氨醇二烯胺的方法
WO2009052443A1 (en) 2007-10-19 2009-04-23 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
FR2924712B1 (fr) 2007-12-06 2012-12-21 Univ Maine Derives du gossypol et de l'apogossypol, leurs preparations et leurs applications
GB0725077D0 (en) * 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
WO2009126172A1 (en) * 2008-04-11 2009-10-15 The Trustees Of Columbia University In The City Of New York Resistance to polyphenon e due to increased bcl-2 expression
CA2733930A1 (en) * 2008-08-14 2010-02-18 The Uab Research Foundation Anti-arrhythmia agents, methods of their use, methods of their identification, and kits therefore
US8487131B2 (en) 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
MX2011010872A (es) 2009-04-15 2012-01-19 Sanford Burnham Med Res Inst Inhibidores basados en naftaleno de proteinas anti-apoptoticas.
US8772264B2 (en) 2009-08-04 2014-07-08 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
CA2773576C (en) 2009-10-08 2015-12-22 Sanford-Burnham Medical Research Institute Apogossypolone derivatives as anticancer agents
WO2014127191A1 (en) * 2013-02-15 2014-08-21 The Regents Of The University Of Michigan Compositions and methods relating to hindering dot1l recruitment by mll-fusion proteins
US9180226B1 (en) 2014-08-07 2015-11-10 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US9655998B2 (en) 2014-08-07 2017-05-23 Cook Medical Technologies Llc Encapsulated drug compositions and methods of use thereof
US11241520B2 (en) 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
RU2654711C1 (ru) * 2017-07-10 2018-05-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, обладающее апоптоз-индуцирующей активностью
KR102432499B1 (ko) * 2018-04-20 2022-08-12 나이키 이노베이트 씨.브이. 플레이트들 및 개재된 유체 충전 블래더를 구비하는 솔 구조체 및 제조 방법
CN110128290B (zh) * 2019-05-10 2022-04-29 江苏耐雀生物工程技术有限公司 红倍酚苯甲酰肼衍生物、中间体、制备方法及其应用
EP4035313B1 (en) * 2019-09-24 2025-10-01 Genetec Inc. Intermediary device for daisy chain and tree configuration in hybrid data/power connection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
JPH1036260A (ja) * 1996-07-18 1998-02-10 Mitsui Norin Kk 抗ガン剤の効力増強方法
US5804567A (en) * 1996-07-18 1998-09-08 Cancer Institute (Hospital), Chinese Academy Of Medical Sciences Method of increasing the effectiveness of anti-metabolites
US6428818B1 (en) * 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
MY134562A (en) * 2000-12-15 2007-12-31 Wackvom Ltd Methods and compositions to treat conditions associated with neovascularization
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
ES2349349T3 (es) * 2001-05-30 2010-12-30 The Regents Of The University Of Michigan Asociacion sinergica de (-)-gosipol con docetaxel o paclitaxel para el tratamiento de cancer.
DE602004012279T3 (de) * 2003-06-25 2010-07-15 The Burnham Institute, La Jolla Katecholderivate zur behandlung von krebs

Also Published As

Publication number Publication date
DE602004012279D1 (de) 2008-04-17
PL1653943T6 (pl) 2009-02-27
EP1653943B1 (en) 2008-03-05
DK1653943T3 (da) 2008-06-23
JP2012025767A (ja) 2012-02-09
EP1653943B3 (en) 2008-07-30
JP2007524633A (ja) 2007-08-30
ES2303096T3 (es) 2008-08-01
ATE387911T1 (de) 2008-03-15
DE602004012279T3 (de) 2010-07-15
SI1653943T1 (sl) 2008-08-31
US7812058B2 (en) 2010-10-12
ES2303096T7 (es) 2009-06-18
US20120269901A1 (en) 2012-10-25
CA2529507C (en) 2011-08-09
WO2005009434A2 (en) 2005-02-03
EP1653943A2 (en) 2006-05-10
CA2529507A1 (en) 2005-02-03
US20050027000A1 (en) 2005-02-03
ATE478663T1 (de) 2010-09-15
AU2004258867A1 (en) 2005-02-03
DK1653943T4 (da) 2008-12-01
EP1938816A2 (en) 2008-07-02
EP1938816B1 (en) 2010-08-25
ES2351581T3 (es) 2011-02-08
DE602004028880D1 (de) 2010-10-07
PL1653943T3 (pl) 2008-09-30
DE602004012279T2 (de) 2009-07-16
AU2004258867B2 (en) 2010-02-18
US8367644B2 (en) 2013-02-05
EP1938816A3 (en) 2008-08-06
US20110111057A1 (en) 2011-05-12
WO2005009434A3 (en) 2005-06-09
DE602004012279T9 (de) 2010-01-28

Similar Documents

Publication Publication Date Title
PT1653943E (pt) Derivados de catecol para o tratamento do cancro
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
SE0104334D0 (sv) Therapeutic agents
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
GB0318447D0 (en) Therapeutic agents
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
NZ598489A (en) Combination therapy for treating proliferative diseases
WO2005000863A3 (en) 6, 11-4c-bicyclic 9a-azalide derivatives
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
BR0113389A (pt) Compostos que inibem a atividade do fator xa
DE60014916D1 (de) Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung
EP1177791A3 (en) Use of glycogen phosphorylase inhibitors to inhibit tumor growth
NO20004162L (no) Antitumor agens
TW200510384A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
TW200634021A (en) 3,6-bicyclolides
SE0201837D0 (sv) Chemical compounds
WO2002074756A3 (de) Urokinase-inhibitoren
SE9901572D0 (sv) New compounds
BRPI0513549A (pt) composições farmacêuticas para o tratamento de leishmaniose
SG166799A1 (en) Quinoline derivatives as antibacterial agents
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
TW200640464A (en) Pharmaceutical composition comprising phenoxazinium compounds as an active ingredient
SE0103272D0 (sv) Chemical compounds
EP4558144A1 (en) Quinolylnitrone derivatives for use in the prevention and/or treatment of hearing loss